Health ❯ Healthcare ❯ Patient Care ❯ Treatment Efficacy

PASI Response Rates

Takeda’s AI-Assisted Psoriasis Pill Succeeds in Phase 3, Outperforms Otezla

Takeda targets regulatory filings in fiscal 2026 after presenting full results at upcoming medical meetings.